title: [The Possibility of Epidermal Growth Factor Receptor Inhibition in Anal Cancer].
abstract: Anal cancer is a relatively rare tumour. In local and locally advanced disease, concomitant chemoradiation based on mitomycin C and 5-fluorouracil, remains golden standard of treatment. However, this treatment is associated with significant morbidity. With the developing of molecular biology, new treatment strategies can be investigated. Epidermal growth factor receptor (EGFR) expression in anal cancer is observed in 55-100% of cases. Some studies demonstrated that KRAS mutations, mechanism marker of resistance to antiEGFR therapy, are rare in anal cancer. This paper presents current view on the possibilities of antiEGFR therapy in locally advanced and metastatic anal cancer.
authors: I
authors: I
authors: Richter
authors: J
authors: J
authors: Dvořák
authors: T
authors: T
authors: Jirásek
authors: J
authors: J
authors: Bartoš
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D001005:Anus Neoplasms / Q000188:drug therapy* / Q000473:pathology; D066246:ErbB Receptors / Q000037:antagonists & inhibitors*; D006801:Humans; D009362:Neoplasm Metastasis
chemical_list: D000911:Antibodies, Monoclonal; D066246:ErbB Receptors